EyePoint closes upsized $161M public offering; net proceeds ~$151.1M for DURAVYU development

EyePoint, Inc.

Closed offering of 14,636,363 shares at $11.00/share, including full underwriter option exercise for 1,909,090 additional shares.
Net proceeds of ~$151.1M after underwriting discounts and expenses; original offering was upsized from $125M to $161M gross.
Proceeds to fund DURAVYU clinical development for wet AMD & DME, early-stage pipeline, and general corporate purposes.
Joint book-runners: J.P. Morgan, Citigroup, Guggenheim Securities; co-managers: Baird, Mizuho, Jones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.